Divya Chauhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Divya Chauhan has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Manish Kumar Chourasia
CSIR-Central Drug Research Institute
6 shared publications - Pavan Kumar Yadav
Division of Pharmaceutics & Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India
6 shared publications Arun Agarwal
Division of Pharmaceutics & Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, 226031, Uttar Pradesh, India
3 shared publicationsJiaur R Gayen
Division of Pharmaceutics & Pharmacokinetics, CSIR–Central Drug Research Institute, Lucknow, 226031, India
3 shared publications- Jiaur Rahaman Gayen
Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India
3 shared publications - Pooja Yadav
Division of Pharmaceutics & Pharmacokinetics, CSIR–Central Drug Research Institute, Lucknow, 226031, India
3 shared publications
Latest Publications
- 3 September 2024
- Published by Taylor & Francis in Nanomedicine
- Vol. 19 (25) , 2085-2097
LC-MS/MS method for simultaneous Doxorubicin and Baicalein estimation: formulation and pharmacokinetic applications
Aim & objective: Combinatorial delivery of Doxorubicin (DOX) and Baicalein (BAC) has a potential to improve breast cancer treatment by mitigating the cardiotoxicity induced by DOX. The nanoformulation has been optimized and subjected to pharmacokinetic studies using LC-MS/MS.Materials & methods: Nanoformulation bearing DOX and BAC was optimized using quality by design approach and method validation was done following USFDA guidelines.Results: The particle size, PDI and zeta potential of developed nanoformulation were 162.56 ± 2.21 nm, 0.102 ± 0.03 and -16.5 ± 1.21 mV, respectively. DOX-BAC-SNEDDs had a higher AUC0-t values of 6128.84 ± 68.71 and 5896.62 ± 99.31 ng/mL/h as compared with DOX-BAC suspension.Conclusion: These findings hold promise for advancing breast cancer treatment and facilitating therapeutic drug monitoring.
- 3 September 2024
- Published by Taylor & Francis in Nanomedicine
- Vol. 19 (25) , 2085-2097
LC-MS/MS method for simultaneous Doxorubicin and Baicalein estimation: formulation and pharmacokinetic applications
Aim & objective: Combinatorial delivery of Doxorubicin (DOX) and Baicalein (BAC) has a potential to improve breast cancer treatment by mitigating the cardiotoxicity induced by DOX. The nanoformulation has been optimized and subjected to pharmacokinetic studies using LC-MS/MS.Materials & methods: Nanoformulation bearing DOX and BAC was optimized using quality by design approach and method validation was done following USFDA guidelines.Results: The particle size, PDI and zeta potential of developed nanoformulation were 162.56 ± 2.21 nm, 0.102 ± 0.03 and -16.5 ± 1.21 mV, respectively. DOX-BAC-SNEDDs had a higher AUC0-t values of 6128.84 ± 68.71 and 5896.62 ± 99.31 ng/mL/h as compared with DOX-BAC suspension.Conclusion: These findings hold promise for advancing breast cancer treatment and facilitating therapeutic drug monitoring.
- 8 August 2024
- Published by Taylor & Francis in Nanomedicine
- Vol. 19 (24) , 1995-2010
Simultaneous estimation of paclitaxel and bortezomib via LC-MS/MS: pharmaceutical and pharmacokinetic applications
Aim & Objective: This study evaluates the potential of combining paclitaxel (PTX) and bortezomib (BTZ) for breast cancer therapy. Materials & Methods: The nanoformulation was optimized via Box-Behnken Design (BBD), with method validation adhering to US-FDA guidelines. Results: Multiple reaction monitoring transitions for PTX, BTZ and internal standard were m/z 855.80→286.60, 366.80→226.00 and 179.80→110.00, respectively. Elution done on C18 Luna column with 0.1% FA in MeOH:10 mM ammonium acetate. The size of nanoformulation was 133.9 ± 1.97 nm, PDI 0.19 ± 0.01 and zeta potential -19.20 ± 1.36 mV. Pharmacokinetics showed higher Cmax for PTX-BTZ-NE (313.75 ± 10.71 ng/ml PTX, 11.92 ± 0.53 ng/ml BTZ) versus free PTX-BTZ (104 ± 13.06 ng/ml PTX, 1.9 ± 0.08 ng/ml BTZ). Conclusion: Future findings will contribute to the treatment of breast cancer using PTX and BTZ.
- 8 August 2024
- Published by Taylor & Francis in Nanomedicine
- Vol. 19 (24) , 1995-2010
Simultaneous estimation of paclitaxel and bortezomib via LC-MS/MS: pharmaceutical and pharmacokinetic applications
Aim & Objective: This study evaluates the potential of combining paclitaxel (PTX) and bortezomib (BTZ) for breast cancer therapy. Materials & Methods: The nanoformulation was optimized via Box-Behnken Design (BBD), with method validation adhering to US-FDA guidelines. Results: Multiple reaction monitoring transitions for PTX, BTZ and internal standard were m/z 855.80→286.60, 366.80→226.00 and 179.80→110.00, respectively. Elution done on C18 Luna column with 0.1% FA in MeOH:10 mM ammonium acetate. The size of nanoformulation was 133.9 ± 1.97 nm, PDI 0.19 ± 0.01 and zeta potential -19.20 ± 1.36 mV. Pharmacokinetics showed higher Cmax for PTX-BTZ-NE (313.75 ± 10.71 ng/ml PTX, 11.92 ± 0.53 ng/ml BTZ) versus free PTX-BTZ (104 ± 13.06 ng/ml PTX, 1.9 ± 0.08 ng/ml BTZ). Conclusion: Future findings will contribute to the treatment of breast cancer using PTX and BTZ.
- 19 April 2024
- Published by Taylor & Francis in Nanomedicine
- Vol. 19 (12) , 1051-1068
Enhanced oral bioavailability of levormeloxifene and raloxifene by nanoemulsion: simultaneous bioanalysis using liquid chromatography-tandem mass spectrometry
Aim & objective: Levormeloxifene (L-ORM) and raloxifene (RAL) are selective estrogen receptor modulators used in the treatment of postmenopausal osteoporosis and breast cancer. Here, we developed a... Graphical abstract
- 19 April 2024
- Published by Taylor & Francis in Nanomedicine
- Vol. 19 (12) , 1051-1068
Enhanced oral bioavailability of levormeloxifene and raloxifene by nanoemulsion: simultaneous bioanalysis using liquid chromatography-tandem mass spectrometry
Aim & objective: Levormeloxifene (L-ORM) and raloxifene (RAL) are selective estrogen receptor modulators used in the treatment of postmenopausal osteoporosis and breast cancer. Here, we developed a... Graphical abstract
- 10 January 2024
- Published by Taylor & Francis in Bioanalysis
- Vol. 16 (3) , 141-153
LC–MS/MS Method for Simultaneous Estimation of Raloxifene, Cladrin in rat Plasma: Application in Pharmacokinetic Studies
Aim: A newer LC–MS/MS method was developed and validated for the simultaneous quantification of raloxifene (RL) and cladrin (CL). Methodology: Both drugs were resolved in RP-18 (4.6 × 50 mm, 5 μ) X... Graphical abstract
- 10 January 2024
- Published by Taylor & Francis in Bioanalysis
- Vol. 16 (3) , 141-153
LC–MS/MS Method for Simultaneous Estimation of Raloxifene, Cladrin in rat Plasma: Application in Pharmacokinetic Studies
Aim: A newer LC–MS/MS method was developed and validated for the simultaneous quantification of raloxifene (RL) and cladrin (CL). Methodology: Both drugs were resolved in RP-18 (4.6 × 50 mm, 5 μ) X... Graphical abstract
- 31 May 2023
- Published by Taylor & Francis in Bioanalysis
- Vol. 15 (11) , 601-620
Simultaneous Estimation of Raloxifene and Cladrin by HPLC: Application to Metabolic Stability Studies in Different Species
Aim: A reliable, sensitive, HPLC method was developed and validated to simultaneously quantify raloxifene (RLX) and cladrin (CLD). Method: The C18 column was used to analyze RLX and CLD at λmax 285...
- 31 May 2023
- Published by Taylor & Francis in Bioanalysis
- Vol. 15 (11) , 601-620
Simultaneous Estimation of Raloxifene and Cladrin by HPLC: Application to Metabolic Stability Studies in Different Species
Aim: A reliable, sensitive, HPLC method was developed and validated to simultaneously quantify raloxifene (RLX) and cladrin (CLD). Method: The C18 column was used to analyze RLX and CLD at λmax 285...
- 1 February 2023
- Published by Taylor & Francis in Nanomedicine
- Vol. 18 (4) , 343-366
Enhanced Apoptosis and Mitochondrial Cell Death by Paclitaxel-Loaded TPP-TPGS 1000 -Functionalized Nanoemulsion
Background: The present research was designed to develop a nanoemulsion (NE) of triphenylphosphine-D-α-tocopheryl-polyethylene glycol succinate (TPP-TPGS1000) and paclitaxel (PTX) to effectively de... Graphical abstract
- 1 February 2023
- Published by Taylor & Francis in Nanomedicine
- Vol. 18 (4) , 343-366
Enhanced Apoptosis and Mitochondrial Cell Death by Paclitaxel-Loaded TPP-TPGS 1000 -Functionalized Nanoemulsion
Background: The present research was designed to develop a nanoemulsion (NE) of triphenylphosphine-D-α-tocopheryl-polyethylene glycol succinate (TPP-TPGS1000) and paclitaxel (PTX) to effectively de... Graphical abstract